Shots: The US FDA has approved FoundationOne CDx to be used as a CDx for Alunbrig (brigatinib) which is approved for the treatment of adult patients with ALK+ mNSCLC as […]readmore
Tags : brigatinib
Shots: The EC’s approval is based on P-III ALTA-1L study assessing Alunbrig (180mg, qd with seven-day lead-in at 90mg, qd) vs crizotinib (250mg, bid) in 275 patients with ALK+ LA/m-NSCLC […]readmore
Shots: The US FDA has granted PR to Takeda’s sNDA for the expanded use of Alunbrig (brigatinib) as 1L treatment for patients with ALK+ metastatic NSCLC detected by FDA-approved test […]readmore
Shots: The P-III ALTA-1L study involves assessing of Alunbrig (180mg, qd for 7days lead in 90mg qd) vs Crizotinib (250mg, bid) in 275 patients with anaplastic lymphoma kinase-positive (ALK+) LA/ […]readmore